Floatz logo

Bumetanide

Cirrhosis

Stacy JohnsonSmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Cirrhosis cohort.

Asset / SponsorPhaseRating
PARITAPREVIR
AbbVie
Phase 3A
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB
NORMAL HUMAN SERUM ALBUMIN
King George's Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Bumetanide is also rated in:

Parkinson diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
Alzheimer diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →